Pharming Narrows 2026 Revenue Guidance to USD 380 Million–390 Million

• Pharming Group narrowed 2026 revenue guidance to US$ 380 million–US$ 390 million from US$ 375 million–US$ 395 million.
• Full-year operating expense guidance fell to US$ 310 million–US$ 315 million from US$ 315 million–US$ 320 million.
• Preliminary third-quarter revenue rose 21% year over year to approximately US$ 117.6 million, exceeding analyst expectations.
• Quarterly operating expenses were approximately US$ 74.6 million, broadly unchanged year over year and below analyst consensus.
• Revenue growth reflected recovering US demand for RUCONEST, more US patients receiving paid Joenja therapy and increased international demand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220100PRIMZONEFULLFEED1001279225) on October 22, 2026, and is solely responsible for the information contained therein.